Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study

Plain-language summary

This study investigates the role of the steroid Betamethasone in familial amyotrophic lateral sclerosis (ALS) linked to the FUS gene. People aged 20-80 who have familial ALS, or who are relatives of an ALS patient and carry the FUS gene, may take part. The study was conducted in Early Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Completed

Sponsor

Edward Kasaraskis

Intervention

Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days

Start date

8/21/2017

Estimated completion

1/10/2019

Countries

United States

Related genes

Locations

• Lexington, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of familial ALS (fALS)
* Relative of a fALS person and carry the FUS gene

Exclusion Criteria:

* Under 20 years or over 80 years of age
* Cannot tolerate steroids, including betamethasone
* Are unwilling or unable to attend all scheduled research visits
* Currently participating in another clinical drug trial
* Major neurological disease, other than ALS
* Pregnant